Announcements Trials

Browse Landscape

Phase

Status

Completed 7 Recruiting 2 Unknown 1 Approved for marketing 1

Sponsor Class

OTHER 3 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 180 Breast Neoplasms 173 Carcinoma, Non-Small-Cell Lung 172 Colorectal Neoplasms 104 Stomach Neoplasms 80 Pancreatic Neoplasms 78 Lung Neoplasms 78 Prostatic Neoplasms 74 Melanoma 67 Recurrence 65 Leukemia, Myeloid, Acute 65 Neoplasm Metastasis 64 Multiple Myeloma 63 Ovarian Neoplasms 61 Carcinoma, Hepatocellular 61 Advanced Solid Tumor 59 Lymphoma 58 Advanced Solid Tumors 56 Solid Tumor 50 Lymphoma, Non-Hodgkin 47 Uterine Cervical Neoplasms 45 Glioblastoma 44 Lymphoma, B-Cell 39 Leukemia 38 Head and Neck Neoplasms 34 Colonic Neoplasms 34 Precursor Cell Lymphoblastic Leukemia-Lymphoma 33 Esophageal Neoplasms 30 Urinary Bladder Neoplasms 29 Squamous Cell Carcinoma of Head and Neck 29

Interventions

Vorinostat 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × INDUSTRY × Neuroectodermal Tumors × Clear all

NCT03561259 2023-02-16

OPTIMUM

Jubilant DraxImage Inc.

Phase 2 Unknown

Neoplasms, Neuroblastoma, Neuroectodermal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡